Improved quality of life in patients with overactive bladder symptoms treated with solifenacin

BJU International

Volumn 95, Issue 1, 2005, Pages 81-85

  Kelleher, Con J ^a   Cardozo, Linda ^b   Chapple, Christopher R ^c   Haab, Francois ^d   Ridder, Arwin M ^e  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d HÔPITAL TENON   (France)

^e ASTELLAS PHARMA INC   (Japan)

Author keywords

Antimuscarinic; Overactive bladder; Quality of life; Solifenacin succinate

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SOLIFENACIN;

ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EMOTION; HUMAN; HUMAN RELATION; KING HEALTH QUESTIONNAIRE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERACTIVE BLADDER; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SOCIAL ASPECT; TREATMENT OUTCOME; URINE INCONTINENCE; DATA ANALYSIS; ENERGY; HEALTH PERCEPTIONS QUESTIONNAIRE; OUTCOME ASSESSMENT; ROLE PLAYING; SCORING SYSTEM; SLEEP; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERPERSONAL RELATIONS; MALE; MULTICENTER STUDIES; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER DISEASES; URINARY INCONTINENCE;

EID: 12544251628     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.05255.x     Document Type: Article

References (21)

1. Abrams P, Wein AJ. Introduction, overactive bladder and its treatments. Urology 2000; 55 (Suppl. 5A): 1-2
2. Thorn DH. Overactive bladder. epidemiology and impact on quality of life. Contemp Ob/Gyn 2000; (Summer Suppl) 6-14
3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
4. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
5. Abrams P, Wein AJ. The Impact of Overactive Bladder on Patients and Society, and Current Approaches to Treatment. CME Monograph. Laguna Miguel, CA: The Institute for Medical Studies (IMS), May 2002
6. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6 (Suppl. 11): 5580-90
7. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (Suppl. 11): S574-9
8. Wagner TH, Hu TW, Bentkover J et al. Health-related consequences of overactive bladder. Am J Manag Care 2002; 8 (Suppl. 19): S598-607
9. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
10. Chapple CR. Randomized, double-blind comparison of once-daily solifenacin succinate versus placebo or tolterodine in patients with overactive bladder (OAB). Can J Urol 2003; 10: 1967, A29
11. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology 2003; 61: 37-49
12. Kelleher C. Quality of life and urinary incontinence. Baillière's Best Pract Res Clin Obstet Gynaecol 2000; 14: 363-79
13. Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999; 83: 583-90
14. Donovan JL, Badia X, Corcos J et al. Symptom and quality of life assessment. In Abrams P, Cardozo L, Khoury S, Wein A eds, Incontinence, 2nd edn. Plymouth: UK Health Publication Ltd, 2002: 267-316
15. Diokno A, Sand P, Labasky R et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002; 34: 43-9
16. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-9
17. Reese PR, Pleil AM, Okano GJ, Kelleher CJ. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003; 12: 427-42
18. Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8: S616-30
19. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: in press
20. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 (Suppl. 5A): 33-46
21. Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001; 57: 1044-50